S5. Sensitivities of significant SLC38A3 LOH associated drugs in ESCC cell lines.
| Type | Drug name | Target | Estimate rho | P |
| SLC38, solute carrier family 38; LOH, loss of heterozygosity; ESCC, esophageal squamous cell carcinoma. | ||||
| SLC38A3_LOH | LN_IC50: KIN001-244 | PDK1 (PDPK1) | −0.513974 | 0.0072 |
| SLC38A3_LOH | LN_IC50: YM201636 | PYKFYVE | −0.474938 | 0.0142 |
| SLC38A3_LOH | LN_IC50: Alectinib | ALK | −0.448914 | 0.0214 |
| SLC38A3_LOH | LN_IC50: NG-25 | TAK1, MAP4K2 | −0.448914 | 0.0214 |
| SLC38A3_LOH | LN_IC50: Cabozantinib | VEGFR, MET, RET, KIT, FLT1, FLT3, FLT4, TIE2, AXL | −0.448914 | 0.0214 |
| SLC38A3_LOH | LN_IC50: rTRAIL | TRAIL receptor agonist | 0.452059 | 0.0266 |
| SLC38A3_LOH | LN_IC50: MG-132 | Proteasome, CAPN1 | 0.724569 | 0.0272 |
| SLC38A3_LOH | LN_IC50: Pyrimethamine | Dihydrofolate reductase (DHFR) | 0.724569 | 0.0272 |
| SLC38A3_LOH | LN_IC50: VX-11e | ERK2 | −0.409878 | 0.0376 |
| SLC38A3_LOH | LN_IC50: PI-103 | PI3Kalpha, DAPK3, CLK4, PIM3, HIPK2 | −0.416025 | 0.0386 |
| SLC38A3_LOH | LN_IC50: KIN001-266 | MAP3K8 | −0.396866 | 0.0447 |
| SLC38A3_LOH | LN_IC50: KIN001-260 | IKKB | −0.396866 | 0.0447 |